Cargando…

Treatment and post-operative follow-up of pulmonary sclerosing pneumocytoma: A case report

INTRODUCTION AND IMPORTANCE: Pulmonary sclerosing pneumocytoma (PSP) is a rare tumor thought to originate from respiratory epithelial cells. It is usually benign, but may rarely metastasize to lymph nodes. Surgeons face unique challenges in diagnosis and management of this condition, and ideal surgi...

Descripción completa

Detalles Bibliográficos
Autores principales: Barnes, Katherine E., Wile, Rachel K., Banks, Kian C., Velotta, Jeffrey B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9793125/
https://www.ncbi.nlm.nih.gov/pubmed/36582872
http://dx.doi.org/10.1016/j.amsu.2022.104836
_version_ 1784859788900827136
author Barnes, Katherine E.
Wile, Rachel K.
Banks, Kian C.
Velotta, Jeffrey B.
author_facet Barnes, Katherine E.
Wile, Rachel K.
Banks, Kian C.
Velotta, Jeffrey B.
author_sort Barnes, Katherine E.
collection PubMed
description INTRODUCTION AND IMPORTANCE: Pulmonary sclerosing pneumocytoma (PSP) is a rare tumor thought to originate from respiratory epithelial cells. It is usually benign, but may rarely metastasize to lymph nodes. Surgeons face unique challenges in diagnosis and management of this condition, and ideal surgical management is yet to be established. CASE PRESENTATION: 48-year-old woman with a 7 × 7 mm pulmonary lesion discovered incidentally on computerized tomography (CT) imaging, which grew to 9 mm over the following year. Seven years later, follow-up imaging revealed that the mass had grown to 1.3 cm in largest dimension. Surgery was recommended and the mass was resected via a right video-assisted thoracic surgery (VATS) middle lobectomy with mediastinal lymph node dissection. All lymph nodes were negative and the patient's postoperative course was unremarkable. CLINICAL DISCUSSION: There are few evidence-based guidelines available on the treatment and postoperative surveillance of PSP. Research has shown comparable recurrence-free survival rates for sublobar resection and lobectomy, though recurrence can occur, especially following sublobar resection in larger or more centrally-located tumors. In absence of established guidelines, it was decided to follow this patient according to NCCN guidelines for surveillance of early-stage non-small cell lung cancer due to potential risk of recurrence. CONCLUSION: This case report adds to the limited literature on PSP and depicts a possible treatment and postoperative follow-up plan. Right VATS middle lobectomy can effectively treat some cases of central PSP. In absence of established guidelines for postoperative follow-up of PSP, NCCN guidelines may outline one possible strategy for postoperative management.
format Online
Article
Text
id pubmed-9793125
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-97931252022-12-28 Treatment and post-operative follow-up of pulmonary sclerosing pneumocytoma: A case report Barnes, Katherine E. Wile, Rachel K. Banks, Kian C. Velotta, Jeffrey B. Ann Med Surg (Lond) Case Report INTRODUCTION AND IMPORTANCE: Pulmonary sclerosing pneumocytoma (PSP) is a rare tumor thought to originate from respiratory epithelial cells. It is usually benign, but may rarely metastasize to lymph nodes. Surgeons face unique challenges in diagnosis and management of this condition, and ideal surgical management is yet to be established. CASE PRESENTATION: 48-year-old woman with a 7 × 7 mm pulmonary lesion discovered incidentally on computerized tomography (CT) imaging, which grew to 9 mm over the following year. Seven years later, follow-up imaging revealed that the mass had grown to 1.3 cm in largest dimension. Surgery was recommended and the mass was resected via a right video-assisted thoracic surgery (VATS) middle lobectomy with mediastinal lymph node dissection. All lymph nodes were negative and the patient's postoperative course was unremarkable. CLINICAL DISCUSSION: There are few evidence-based guidelines available on the treatment and postoperative surveillance of PSP. Research has shown comparable recurrence-free survival rates for sublobar resection and lobectomy, though recurrence can occur, especially following sublobar resection in larger or more centrally-located tumors. In absence of established guidelines, it was decided to follow this patient according to NCCN guidelines for surveillance of early-stage non-small cell lung cancer due to potential risk of recurrence. CONCLUSION: This case report adds to the limited literature on PSP and depicts a possible treatment and postoperative follow-up plan. Right VATS middle lobectomy can effectively treat some cases of central PSP. In absence of established guidelines for postoperative follow-up of PSP, NCCN guidelines may outline one possible strategy for postoperative management. Elsevier 2022-11-05 /pmc/articles/PMC9793125/ /pubmed/36582872 http://dx.doi.org/10.1016/j.amsu.2022.104836 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Barnes, Katherine E.
Wile, Rachel K.
Banks, Kian C.
Velotta, Jeffrey B.
Treatment and post-operative follow-up of pulmonary sclerosing pneumocytoma: A case report
title Treatment and post-operative follow-up of pulmonary sclerosing pneumocytoma: A case report
title_full Treatment and post-operative follow-up of pulmonary sclerosing pneumocytoma: A case report
title_fullStr Treatment and post-operative follow-up of pulmonary sclerosing pneumocytoma: A case report
title_full_unstemmed Treatment and post-operative follow-up of pulmonary sclerosing pneumocytoma: A case report
title_short Treatment and post-operative follow-up of pulmonary sclerosing pneumocytoma: A case report
title_sort treatment and post-operative follow-up of pulmonary sclerosing pneumocytoma: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9793125/
https://www.ncbi.nlm.nih.gov/pubmed/36582872
http://dx.doi.org/10.1016/j.amsu.2022.104836
work_keys_str_mv AT barneskatherinee treatmentandpostoperativefollowupofpulmonarysclerosingpneumocytomaacasereport
AT wilerachelk treatmentandpostoperativefollowupofpulmonarysclerosingpneumocytomaacasereport
AT bankskianc treatmentandpostoperativefollowupofpulmonarysclerosingpneumocytomaacasereport
AT velottajeffreyb treatmentandpostoperativefollowupofpulmonarysclerosingpneumocytomaacasereport